Key Regulators of Angiogenesis and Inflammation Are Dysregulated in Patients with Varicose Veins

• Published in: International journal of molecular sciences Vol. 25; no. 12; p. 6785
• Main Authors: Zalewski, Daniel, Chmiel, Paulina, Kołodziej, Przemysław, Kocki, Marcin, Feldo, Marcin, Kocki, Janusz, Bogucka-Kocka, Anna
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 20.06.2024; MDPI
• Subjects: Adult; Aged; Angiogenesis; Body mass index; Cardiovascular disease; Care and treatment; Compression therapy; Coronary heart disease; Female; Gene Expression Regulation; Humans; Hypertension; Inflammation; Inflammation - blood; Inflammation - metabolism; Inflammation - pathology; Leukocytes; Leukocytes, Mononuclear - metabolism; Male; Middle Aged; Mortality; Neovascularization, Pathologic - metabolism; Performance evaluation; Plasma; Poland; Quality of life; Regression analysis; Taiwan; Varicose veins; Varicose Veins - blood; Varicose Veins - metabolism; Varicose Veins - pathology; Vascular endothelial growth factor; Poland; Taiwan; chronic venous disease; plasma proteins; inflammation; varicose veins; angiogenesis; gene expression
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25126785

Varicose veins (VVs) are the most common manifestation of chronic venous disease (CVD) and appear as abnormally enlarged and tortuous superficial veins. VVs result from functional abnormalities in the venous circulation of the lower extremities, such as venous hypertension, venous valve incompetence, and venous reflux. Previous studies indicate that enhanced angiogenesis and inflammation contribute to the progression and onset of VVs; however, dysregulations in signaling pathways associated with these processes in VVs patients are poorly understood. Therefore, in our study, we aimed to identify key regulators of angiogenesis and inflammation that are dysregulated in patients with VVs. Expression levels of 18 genes were analyzed in peripheral blood mononuclear cells (PBMC) using real-time PCR, as well as plasma levels of 6 proteins were investigated using ELISA. Higher levels of CCL5, PDGFA, VEGFC, TGF-alpha, TGF-beta 1, and VEGF-A, as well as lower levels of VEGFB and VEGF-C, were found to be statistically significant in the VV group compared to the control subjects without VVs. None of the analyzed factors was associated with the venous localization of the varicosities. The presented study identified dysregulations in key angiogenesis- and inflammation-related factors in PBMC and plasma from VVs patients, providing new insight into molecular mechanisms that could contribute to the development of VVs and point out promising candidates for circulatory biomarkers of this disease.